Silencing of ANGPTL 3 (angiopoietin-like protein 3) in human hepatocytes results in decreased expression of gluconeogenic genes and reduced triacylglycerol-rich VLDL secretion upon insulin stimulation

Bioscience Reports

Volumn 34, Issue 6, 2014, Pages 811-821

  Tikka, Anna ^a   Soronen, Jarkko ^a,b   Laurila, Pirkka Pekka ^a   Metso, Jari ^a   Ehnholm, Christian ^a   Jauhiainen, Matti ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

Author keywords

ANGPTL3 silencing; Hypolipidaemia; Insulin signalling; Liver; Rosiglitazone; VLDL

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN LIKE PROTEIN 3; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOPOIETIN 1; ANGPT1 PROTEIN, HUMAN; ANTIDIABETIC AGENT; FATTY ACID; VERY LOW DENSITY LIPOPROTEIN TRIGLYCERIDE;

ANGPTL 3 GENE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE SILENCING; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HORMONAL REGULATION; HUMAN; HUMAN CELL; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; INTRACELLULAR SIGNALING; LIPOGENESIS; LIPOPROTEIN SECRETION; LIVER CELL; NUCLEOTIDE SEQUENCE; PHENOTYPE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENETICS; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SECRETION (PROCESS); TRANSFORMED CELL LINE;

ANGIOPOIETIN-1; CELL LINE, TRANSFORMED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY ACIDS; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE; HEPATOCYTES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPOPROTEINS, VLDL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 84919624492     PISSN: 01448463     EISSN: 15734935     Source Type: Journal    
DOI: 10.1042/BSR20140115     Document Type: Article

References (39)

1. Davis, S., Papadopoulos, N., Aldrich, T. H., Maisonpierre, P. C., Huang, T., Kovac, L., Xu, A., Leidich, R., Radziejewska, E., Rafique, A. et al. (2003) Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering. Nat. Struct. Biol. 10, 38-44 CrossRef PubMed
2. Ono, M., Shimizugawa, T., Shimamura, M., Yoshida, K., Noji-Sakikawa, C., Ando, Y., Koishi, R. and Furukawa, H. (2003) Protein region important for regulation of lipid metabolism in angiopoietin-like 3 (ANGPTL3): ANGPTL3 is cleaved and activated in vivo. J. Biol. Chem 278, 41804-41809 CrossRef PubMed
3. Conklin, D., Gilbertson, D., Taft, D. W., Maurer, M. F., Whitmore, T. E., Smith, D. L., Walker, K. M., Chen, L. H., Wattler, S., Nehls, M. and Lewis, K. B. (1999) Identification of a mammalian angiopoietin-related protein expressed specifically in liver. Genomics 62, 477-482 CrossRef PubMed
4. Romeo, S., Yin, W., Kozlitina, J., Pennacchio, L. A., Boerwinkle, E., Hobbs, H. H. and Cohen, J. C. (2009) Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J. Clin. Invest. 119, 70-79 PubMed
5. Liu, J., Afroza, H., Rader, D. J. and Jin, W. (2010) Angiopoietin-like protein 3 inhibits lipoprotein lipase activity through enhancing its cleavage by proprotein convertases. J. Biol. Chem. 285, 27561-27570 CrossRef PubMed
6. Lee, E. C., Desai, U., Gololobov, G., Hong, S., Feng, X., Yu, X. C., Gay, J., Wilganowski, N., Gao, C., Du, L. L. et al. (2009) Identification of a new functional domain in angiopoietin-like 3 (ANGPTL3) and angiopoietin-like 4 (ANGPTL4) involved in binding and inhibition of lipoprotein lipase (LPL). J. Biol. Chem. 284, 13735-13745 CrossRef PubMed
7. Shan, L., Yu, X. C., Liu, Z., Hu, Y., Sturgis, L. T., Miranda, M. L. and Liu, Q. (2009) The angiopoietin-like proteins ANGPTL3 and ANGPTL4 inhibit lipoprotein lipase activity through distinct mechanisms. J. Biol. Chem. 284, 1419-1424 CrossRef PubMed
8. Koishi, R., Ando, Y., Ono, M., Shimamura, M., Yasumo, H., Fujiwara, T., Horikoshi, H. and Furukawa, H. (2002) Angptl3 regulates lipid metabolism in mice. Nat. Genet. 30, 151-157 CrossRef PubMed
9. Shimizugawa, T., Ono, M., Shimamura, M., Yoshida, K., Ando, Y., Koishi, R., Ueda, K., Inaba, T., Minekura, H., Kohama, T. and Furukawa, H. (2002) ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. J. Biol. Chem. 277, 33742-33748 CrossRef PubMed
10. Kathiresan, S., Melander, O., Guiducci, C., Surti, A., Burtt, N. P., Rieder, M. J., Cooper, G. M., Roos, C., Voight, B. F., Havulinna, A. S. et al. (2008) Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat. Genet. 40, 189-197 CrossRef PubMed
11. Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J. et al. (2010) Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466, 707-713 CrossRef PubMed
12. Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M. et al. (2008) Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat. Genet. 40, 161-169 CrossRef PubMed
13. Musunuru, K., Pirruccello, J. P., Do, R., Peloso, G. M., Guiducci, C., Sougnez, C., Garimella, K. V., Fisher, S., Abreu, J., Barry, A. J. et al. (2010) Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N. Engl. J. Med. 363, 2220-2227 CrossRef PubMed
14. Robciuc, M. R., Maranghi, M., Lahikainen, A., Rader, D., Bensadoun, A., Öörni, K., Metso, J., Minicocci, I., Ciociola, E., Ceci, F. et al. (2013) ANGPTL3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids. Arterioscler. Thromb. Vasc. Biol. 33, 1706-1713 CrossRef PubMed
15. Minicocci, I., Montali, A., Robciuc, M. R., Quagliarini, F., Censi, V. and Labbadia, G. (2012) Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a clinical and biochemical characterization. J. Clin. Endocrinol. Metab. 97, E1266-E1275 CrossRef PubMed
16. Malmström, R., Packard, C. J., Caslake, M., Bedford, D., Stewart, P., Yki-Järvinen, H., Shepherd, J. and Taskinen, M. R. (1997) Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 40, 454-462 CrossRef PubMed
17. Garvey, W. T., Kwon, S., Zheng, D., Shaughnessy, S., Wallace, P. and Hutto, A. (2003) Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 52, 453-462 CrossRef PubMed
18. Wu, Z., Jiao, P., Huang, X., Feng, B., Feng, Y., Yang, S., Hwang, P., Du, J., Nie, Y., Xiao, G. and Xu, H. (2010) MAPK phosphatase-3 promotes hepatic gluconeogenesis through dephosphorylation of forkhead box O1 in mice. J. Clin. Invest. 120, 3901-3911 CrossRef PubMed
19. Wu, C., Okar, D. A., Kang, J. and Lange, A. J. (2005) Reduction of hepatic glucose production as a therapeutic target in the treatment of diabetes. Curr. Drug Targets Immune Endocr. Metabol Disord. 5, 51-59 CrossRef PubMed
20. Chirieac, D. V., Davidson, N. O., Sparks, C. E. and Sparks, J. D. (2006) PI3-kinase activity modulates apo B available for hepatic VLDL production in apobec-1-/- mice. Am. J. Physiol. Gastrointest. Liver Physiol. 291, G382-G388 CrossRef PubMed
21. Postic, C., Burcelin, R., Rencurel, F., Pegorier, J. P., Loizeau, M., Girard, J. and Leturque, A. (1993) Evidence for a transient inhibitory effect of insulin on GLUT2 expression in the liver: studies in vivo and in vitro. Biochem. J. 293, 119-124 PubMed
22. Robciuc, M. R., Tahvanainen, E., Jauhiainen, M. and Ehnholm, C. (2010) Quantitation of serum angiopoietin-like proteins 3 and 4 in a Finnish population sample. J. Lipid Res. 51, 824-831 CrossRef PubMed
23. Adiels, M., Westerbacka, J., Soro-Paavonen, A., Häkkinen, A. M., Vehkavaara, S., Caslake, M. J., Packard, C., Olofsson, S. O., Yki-Järvinen, H., Taskinen, M. R. and Borén, J. (2007) Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance. Diabetologia 50, 2356-2365 CrossRef PubMed
24. Rother, K. I., Imai, Y., Caruso, M., Beguinot, F., Formisano, P. and Accili, D. (1998) Evidence that IRS-2 phosphorylation is required for insulin action in hepatocytes. J. Biol. Chem. 273, 17491-17497 CrossRef PubMed
25. Shimamura, M, Matsuda, M., Kobayashi, S., Ando, Y., Ono, M., Koishi, R., Furukawa, H., Makishima, M. and Shimomura, I. (2003) Angiopoietin-like protein 3, a hepatic secretory factor, activates lipolysis in adipocytes. Biochem. Biophys. Res. Commun. 301, 604-609 CrossRef PubMed
26. Carpentier, A., Taghibiglou, C., Leung, N., Szeto, L., Van Iderstine, S. C., Uffelman, K. D., Buckingham, R., Adeli, K. and Lewis, G. F. (2002) Ameliorated hepatic insulin resistance is associated with normalization of microsomal triglyceride transfer protein expression and reduction in very low density lipoprotein assembly and secretion in the fructose-fed hamster. J. Biol. Chem. 277, 28795-28802 CrossRef PubMed
27. Brackenridge, A. L., Jackson, N., Jefferson, W., Stolinski, M., Shojaee-Moradie, F., Hovorka, R., Umpleby, A. M. and Russell-Jones, D. (2009) Effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with Type 2 diabetes and normal lipids. Diabet. Med. 26, 532-539 CrossRef PubMed
28. Rogue, A., Renaud, M. P., Claude, N., Guillouzo, A. and Spire, C. (2011) Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in rat hepatocytes. Toxicol. Appl. Pharmacol. 254, 18-31 CrossRef PubMed
29. Shimamura, M., Matsuda, M., Ando, Y., Koishi, R., Yasumo, H., Furukawa, H. and Shimomura, I. (2004) Leptin and insulin down-regulate angiopoietin-like protein 3, a plasma triglyceride-increasing factor. Biochem. Biophys. Res. Commun. 322, 1080-1085 CrossRef PubMed
30. Ando, Y., Shimizugawa, T., Takeshita, S., Ono, M., Shimamura, M., Koishi, R. and Furukawa, H. (2003) Decreased expression of angiopoietin-like 3 is protective against atherosclerosis in apoE-deficient mice. J. Lipid. Res. 44, 1216-1223 CrossRef PubMed
31. Inukai, K., Nakashima, Y., Watanabe, M., Kurihara, S., Awata, T., Katagiri, H., Oka, Y. and Katayama, S. (2004) ANGPTL3 is increased in both insulin-deficient and -resistant diabetic states. Biochem. Biophys. Res. Commun. 317, 1075-1079 CrossRef PubMed
32. Moore, M. C., Coate, K. C., Winnick, J. J., An, Z. and Cherrington, A. D. (2012) Regulation of hepatic glucose uptake and storage in vivo. Adv. Nutr. 3, 286-294 CrossRef PubMed
33. Minicocci, I., Santini, S., Cantisani, V., Stitziel, N., Kathiresan, S., Arroyo, J. A., Martí, G., Pisciotta, L., Noto, D., Cefalù, A. B. et al. (2013) Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis. J. Lipid Res. 54, 3481-3490 CrossRef PubMed
34. Way, J. M., Harrington, W. W., Brown, K. K., Gottschalk, W. K., Sundseth, S. S., Mansfield, T. A., Ramachandran, R. K., Willson, T. M. and Kliewer, S. A. (2001) Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 142, 1269-1277 PubMed
35. Kim, H. I. and Ahn, Y. H. (2004) Role of peroxisome proliferator-activated receptor-gamma in the glucose-sensing apparatus of liver and beta-cells. Diabetes 53, S60-S65 CrossRef PubMed
36. Yoon, J. C., Puigserver, P., Chen, G., Donovan, J., Wu, Z., Rhee, J., Adelmant, G., Stafford, J., Kahn, C. R., Granner, D. K. et al. (2001) Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 413, 131-138 CrossRef PubMed
37. Koo, S. H., Satoh, H., Herzig, S., Lee, C. H., Hedrick, S., Kulkarni, R., Evans, R. M., Olefsky, J. and Montminy, M. (2004) PGC-1 promotes insulin resistance in liver through PPAR-alphadependent induction of TRB-3. Nat. Med. 10, 530-534 CrossRef PubMed
38. Finck, B. N. and Kelly, D. P. (2006) PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J. Clin. Invest. 116, 615-622 CrossRef PubMed
39. Olson, A. L. and Pessin, J. E. (1996) Structure, function, and regulation of the mammalian facilitative glucose transporter gene family. Annu. Rev. Nutr. 16, 235-256 CrossRef PubMed